Intramuscular delivery of a single chain antibody gene prevents brain Aβ deposition and cognitive impairment in a mouse model of Alzheimer's disease

Brain, Behavior, and Immunity

Volumn 24, Issue 8, 2010, Pages 1281-1293

  Wang, Yan Jiang ^a,b   Gao, Chang Yue ^a,b   Yang, Miao ^a   Liu, Xiao Hong ^a   Sun, Yin ^a   Pollard, Anthony ^a   Dong, Xiao Yan ^c,d   Wu, Xiao Bing ^c   Zhong, Jin Hua ^a   Zhou, Hua Dong ^b   Zhou, Xin Fu ^a  

^a FLINDERS UNIVERSITY   (Australia)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

^c CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^d Beijing Fiveplus Molecular Medicine Institute   (China)

Author keywords

Adeno associated virus; Alzheimer's disease; Amyloid beta; Gene therapy; Immunotherapy; Inflammation; Microhemorrhage; Single chain antibody

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; NEUTRALIZING ANTIBODY; PARVOVIRUS VECTOR; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENCEPHALITIS; GENE EXPRESSION; HIPPOCAMPUS; IMMUNOGENICITY; IMMUNOTHERAPY; LIVER; MICROGLIA; MOUSE; NEOCORTEX; NEUROPATHOLOGY; NONHUMAN; OLFACTORY BULB; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENILE PLAQUE; TRANSGENE; VIRAL GENE DELIVERY SYSTEM;

ALZHEIMER VACCINES; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BRAIN CHEMISTRY; COGNITION DISORDERS; CYTOKINES; DEPENDOVIRUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENETIC VECTORS; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; INJECTIONS, INTRAMUSCULAR; MICE; MICE, TRANSGENIC; PRESENILINS; SINGLE-CHAIN ANTIBODIES;

EID: 77957233161     PISSN: 08891591     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbi.2010.05.010     Document Type: Article

References (52)

1. Bayer A.J., Bullock R., Jones R.W., Wilkinson D., Paterson K.R., Jenkins L., Millais S.B., Donoghue S. Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD. Neurology 2005, 64:94-101.
2. Brantly M.L., Chulay J.D., Wang L., Mueller C., Humphries M., Spencer L.T., Rouhani F., Conlon T.J., Calcedo R., Betts M.R., Spencer C., Byrne B.J., Wilson J.M., Flotte T.R. Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy. Proc. Natl Acad. Sci. USA 2009, 106:16363-16368.
3. Brantly M.L., Spencer L.T., Humphries M., Conlon T.J., Spencer C.T., Poirier A., Garlington W., Baker D., Song S., Berns K.I., Muzyczka N., Snyder R.O., Byrne B.J., Flotte T.R. Phase I trial of intramuscular injection of a recombinant adeno-associated virus serotype 2 alphal-antitrypsin (AAT) vector in AAT-deficient adults. Hum. Gene Ther. 2006, 17:1177-1186.
4. Cai J., Wang S., Zhong Y., Cheng J., Ji Z., Sheng S., Zhang C. Screening and characterization of human single-chain Fv antibody against beta-amyloid peptide 40. NeuroReport 2003, 14:265-268.
5. Cardinale A., Biocca S. The potential of intracellular antibodies for therapeutic targeting of protein-misfolding diseases. Trends Mol. Med. 2008, 14:373-380.
6. Chirino A.J., Ary M.L., Marshall S.A. Minimizing the immunogenicity of protein therapeutics. Drug Discov. Today 2004, 9:82-90.
7. DeMattos R.B., Bales K.R., Cummins D.J., Dodart J.C., Paul S.M., Holtzman D.M. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc. Natl Acad. Sci. USA 2001, 98:8850-8855.
8. Ferrer I., Boada Rovira M., Sanchez Guerra M.L., Rey M.J., Costa-Jussa F. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol. 2004, 14:11-20.
9. Flotte T.R. Gene therapy progress and prospects: recombinant adeno-associated virus (rAAV) vectors. Gene Ther. 2004, 11:805-810.
10. Food and Drug Administration HHS Guidance for industry and reviewers. Estimating the safe starting dose in clinical trials for therapeutics in adult healthy volunteers. Fed. Regist. 2003, 68:2340-2341.
11. Frenkel D., Solomon B., Benhar I. Modulation of Alzheimer's beta-amyloid neurotoxicity by site-directed single-chain antibody. J. Neuroimmunol. 2000, 106:23-31.
12. Frid P., Anisimov S.V., Popovic N. Congo red and protein aggregation in neurodegenerative diseases. Brain Res. Rev. 2007, 53:135-160.
13. Fukuchi K., Tahara K., Kim H.D., Maxwell J.A., Lewis T.L., Accavitti-Loper M.A., Kim H., Ponnazhagan S., Lalonde R. Anti-Abeta single-chain antibody delivery via adeno-associated virus for treatment of Alzheimer's disease. Neurobiol. Dis. 2006, 23:502-511.
14. George A.J., Holsinger R.M., McLean C.A., Laughton K.M., Beyreuther K., Evin G., Masters C.L., Li Q.X. APP intracellular domain is increased and soluble Abeta is reduced with diet-induced hypercholesterolemia in a transgenic mouse model of Alzheimer disease. Neurobiol. Dis. 2004, 16:124-132.
15. Habicht G., Haupt C., Friedrich R.P., Hortschansky P., Sachse C., Meinhardt J., Wieligmann K., Gellermann G.P., Brodhun M., Gotz J., Halbhuber K.J., Rocken C., Horn U., Fandrich M. Directed selection of a conformational antibody domain that prevents mature amyloid fibril formation by stabilizing Abeta protofibrils. Proc. Natl Acad. Sci. USA 2007, 104:19232-19237.
16. Hock C., Konietzko U., Streffer J.R., Tracy J., Signorell A., Muller-Tillmanns B., Lemke U., Henke K., Moritz E., Garcia E., Wollmer M.A., Umbricht D., de Quervain D.J., Hofmann M., Maddalena A., Papassotiropoulos A., Nitsch R.M. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 2003, 38:547-554.
17. Holmes C., Boche D., Wilkinson D., Yadegarfar G., Hopkins V., Bayer A., Jones R.W., Bullock R., Love S., Neal J.W., Zotova E., Nicoll J.A. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008, 372:216-223.
18. Janus C., Pearson J., McLaurin J., Mathews P.M., Jiang Y., Schmidt S.D., Chishti M.A., Horne P., Heslin D., French J., Mount H.T., Nixon R.A., Mercken M., Bergeron C., Fraser P.E., St George-Hyslop P., Westaway D. Abeta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 2000, 408:979-982.
19. Jiang H., Pierce G.F., Ozelo M.C., de Paula E.V., Vargas J.A., Smith P., Sommer J., Luk A., Manno C.S., High K.A., Arruda V.R. Evidence of multiyear factor IX expression by AAV-mediated gene transfer to skeletal muscle in an individual with severe hemophilia B. Mol. Ther. 2006, 14:452-455.
20. Lafaye P., Achour I., England P., Duyckaerts C., Rougeon F. Single-domain antibodies recognize selectively small oligomeric forms of amyloid beta, prevent Abeta-induced neurotoxicity and inhibit fibril formation. Mol. Immunol. 2009, 46:695-704.
21. Lemere C.A. Developing novel immunogens for a safe and effective Alzheimer's disease vaccine. Prog. Brain Res. 2009, 175:83-93.
22. Lemere C.A., Maier M., Jiang L., Peng Y., Seabrook T.J. Amyloid-beta immunotherapy for the prevention and treatment of Alzheimer disease: lessons from mice, monkeys, and humans. Rejuv. Res. 2006, 9:77-84.
23. Levites Y., Jansen K., Smithson L.A., Dakin R., Holloway V.M., Das P., Golde T.E. Intracranial adeno-associated virus-mediated delivery of anti-pan amyloid beta, amyloid beta40, and amyloid beta42 single-chain variable fragments attenuates plaque pathology in amyloid precursor protein mice. J. Neurosci. 2006, 26:11923-11928.
24. Liu R., Yuan B., Emadi S., Zameer A., Schulz P., McAllister C., Lyubchenko Y., Goud G., Sierks M.R. Single chain variable fragments against beta-amyloid (Abeta) can inhibit Abeta aggregation and prevent abeta-induced neurotoxicity. Biochemistry 2004, 43:6959-6967.
25. Meli G., Visintin M., Cannistraci I., Cattaneo A. Direct in vivo intracellular selection of conformation sensitive antibody domains targeting Alzheimer's amyloid-beta oligomers. J. Mol. Biol. 2009, 387:584-606.
26. Mori S., Takeuchi T., Enomoto Y., Kondo K., Sato K., Ono F., Iwata N., Sata T., Kanda T. Biodistribution of a low dose of intravenously administered AAV-2, 10, and 11 vectors to cynomolgus monkeys. Jpn. J. Infect. Dis. 2006, 59:285-293.
27. Nicoll J.A., Barton E., Boche D., Neal J.W., Ferrer I., Thompson P., Vlachouli C., Wilkinson D., Bayer A., Games D., Seubert P., Schenk D., Holmes C. Abeta species removal after abeta42 immunization. J. Neuropathol. Exp. Neurol. 2006, 65:1040-1048.
28. Nicoll J.A., Wilkinson D., Holmes C., Steart P., Markham H., Weller R.O. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat. Med. 2003, 9:448-452.
29. Paganetti P., Calanca V., Galli C., Stefani M., Molinari M. Beta-site specific intrabodies to decrease and prevent generation of Alzheimer's Abeta peptide. J. Cell Biol. 2005, 168:863-868.
30. Patton R.L., Kalback W.M., Esh C.L., Kokjohn T.A., Van Vickle G.D., Luehrs D.C., Kuo Y.M., Lopez J., Brune D., Ferrer I., Masliah E., Newel A.J., Beach T.G., Castano E.M., Roher A.E. Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis. Am. J. Pathol. 2006, 169:1048-1063.
31. Petrushina I., Ghochikyan A., Mktrichyan M., Mamikonyan G., Movsesyan N., Davtyan H., Patel A., Head E., Cribbs D.H., Agadjanyan M.G. Alzheimer's disease peptide epitope vaccine reduces insoluble but not soluble/oligomeric Abeta species in amyloid precursor protein transgenic mice. J. Neurosci. 2007, 27:12721-12731.
32. Pfeifer M., Boncristiano S., Bondolfi L., Stalder A., Deller T., Staufenbiel M., Mathews P.M., Jucker M. Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science 2002, 298:1379.
33. Racke M.M., Boone L.I., Hepburn D.L., Parsadainian M., Bryan M.T., Ness D.K., Piroozi K.S., Jordan W.H., Brown D.D., Hoffman W.P., Holtzman D.M., Bales K.R., Gitter B.D., May P.C., Paul S.M., DeMattos R.B. Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J. Neurosci. 2005, 25:629-636.
34. Rangan S.K., Liu R., Brune D., Planque S., Paul S., Sierks M.R. Degradation of beta-amyloid by proteolytic antibody light chains. Biochemistry 2003, 42:14328-14334.
35. Rebe S., Solomon B. Deglycosylation of anti-beta amyloid antibodies inhibits microglia activation in BV-2 cellular model. Am. J. Alzheimers Dis. Other Demen. 2005, 20:303-313.
36. Robert R., Dolezal O., Waddington L., Hattarki M.K., Cappai R., Masters C.L., Hudson P.J., Wark K.L. Engineered antibody intervention strategies for Alzheimer's disease and related dementias by targeting amyloid and toxic oligomers. Protein Eng. Des. Sel. 2009, 22:199-208.
37. Rogers J., Shen Y. A perspective on inflammation in Alzheimer's disease. Ann. N. Y. Acad. Sci. 2000, 924:132-135.
38. Rohn T.T., Ivins K.J., Bahr B.A., Cotman C.W., Cribbs D.H. A monoclonal antibody to amyloid precursor protein induces neuronal apoptosis. J. Neurochem. 2000, 74:2331-2342.
39. Salloway S., Sperling R., Gilman S., Fox N.C., Blennow K., Raskind M., Sabbagh M., Honig L.S., Doody R., van Dyck C.H., Mulnard R., Barakos J., Gregg K.M., Liu E., Lieberburg I., Schenk D., Black R., Grundman M. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 2009, 73:2061-2070.
40. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Liao Z., Lieberburg I., Motter R., Mutter L., Soriano F., Shopp G., Vasquez N., Vandevert C., Walker S., Wogulis M., Yednock T., Games D., Seubert P. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999, 400:173-177.
41. St George-Hyslop P.H., Morris J.C. Will anti-amyloid therapies work for Alzheimer's disease?. Lancet 2008, 372:180-182.
42. Taguchi H., Planque S., Sapparapu G., Boivin S., Hara M., Nishiyama Y., Paul S. Exceptional amyloid beta peptide hydrolyzing activity of non-physiological immunoglobulin variable domain scaffolds. J. Biol. Chem. 2008, 238:4712-4714.
43. Tamura Y., Hamajima K., Matsui K., Yanoma S., Narita M., Tajima N., Xin K.Q., Klinman D., Okuda K. The F(ab)'2 fragment of an Abeta-specific monoclonal antibody reduces Abeta deposits in the brain. Neurobiol. Dis. 2005, 20:541-549.
44. Wang Y.J., Pollard A., Zhong J.H., Dong X.Y., Wu X.B., Zhou H.D., Zhou X.F. Intramuscular delivery of a single chain antibody gene reduces brain Abeta burden in a mouse model of Alzheimer's disease. Neurobiol. Aging 2009, 30:364-376.
45. Wang, Y.J., Pollard, A.N., Zhou, H.D., Zhong, J.H., Zhou, X.F., 2006. Characterization of an Alzheimer's Disease Mouse Model Bearing Mutant Genes of Amyloid Precursor Protein and Human presenilin. Proceeding of the Australian Neuroscience Society, Syndney, p. 150.
46. Wang Y.J., Thomas P., Zhong J.H., Bi F.F., Kosaraju S., Pollard A., Fenech M., Zhou X.F. Consumption of grape seed extract prevents amyloid-beta deposition and attenuates inflammation in brain of an Alzheimer's disease mouse. Neurotox. Res. 2009, 15:3-14.
47. Wang Y.J., Valadares D., Sun Y., Wang X., Zhong J.H., Liu X.H., Majd S., Chen L., Gao C.Y., Chen S., Lim Y., Pollard A., Aguilar E., Gai W.P., Yang M., Zhou X.F. Effects of proNGF on neuronal viability, neurite growth and amyloid-beta metabolism. Neurotox. Res. 2010, 17:257-267.
48. Wilcock D.M., Rojiani A., Rosenthal A., Subbarao S., Freeman M.J., Gordon M.N., Morgan D. Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J. Neuroinflammation 2004, 1:24.
49. Wong I., Liao H., Bai X., Zaknic A., Zhong J., Guan Y., Li H.Y., Wang Y.J., Zhou X.F. ProBDNF inhibits infiltration of ED1+ macrophages after spinal cord injury. Brain Behav. Immun. 2010, 24:585-597.
50. Yan H., Guo Y., Zhang P., Zu L., Dong X., Chen L., Tian J., Fan X., Wang N., Wu X., Gao W. Superior neovascularization and muscle regeneration in ischemic skeletal muscles following VEGF gene transfer by rAAV1 pseudotyped vectors. Biochem. Biophys. Res. Commun. 2005, 336:287-298.
51. Yau J.L., McNair K.M., Noble J., Brownstein D., Hibberd C., Morton N., Mullins J.J., Morris R.G., Cobb S., Seckl J.R. Enhanced hippocampal long-term potentiation and spatial learning in aged 11beta-hydroxysteroid dehydrogenase type 1 knock-out mice. J. Neurosci. 2007, 27:10487-10496.
52. Zameer A., Schulz P., Wang M.S., Sierks M.R. Single chain Fv antibodies against the 25-35 Abeta fragment inhibit aggregation and toxicity of Abeta42. Biochemistry 2006, 45:11532-11539.